Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 3/20 | 0.36 |
| ▸ | CCNC | P24863 | 5/20 | 0.35 |
| ▸ | CDK8 | P49336 | 5/20 | 0.35 |
| ▸ | CDK19 | Q9BWU1 | 2/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | ATR | Q13535 | 2/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.30 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29315539 | 0.90 | GRIN2B (0.36) | GRIN2B | |
| SCHEMBL26792311 | 0.87 | CCNC (0.34) | GRIN2BCCNCCDK8TLR8TLR7 | |
| SCHEMBL29329331 | 0.87 | KDM1A (0.35) | GRIN2BTLR8TLR7KDM1AJAK1 | |
| SCHEMBL29315570 | 0.86 | IRAK4 (0.40) | CCNCCDK8TLR8TLR7 | |
| SCHEMBL29315543 | 0.85 | GRIN2B (0.34) | GRIN2BCCNCCDK8TLR8TLR7 | |
| SCHEMBL29315499 | 0.85 | SMN1; SMN2 (0.38) | CCNCCDK8JAK2 | |
| SCHEMBL29315531 | 0.83 | JAK1 (0.39) | GRIN2BKDM1AJAK1JAK2 | |
| SCHEMBL29315533 | 0.83 | MPO (0.38) | TLR8TLR7 | |
| SCHEMBL29314416 | 0.80 | TLR7 (0.37) | TLR8TLR7PIK3CA | |
| SCHEMBL29315507 | 0.79 | TLR7 (0.35) | GRIN2BTLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037344-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | GRIN2B 1288/4885CCNC 4144/4885CDK8 3965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.